Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod placebo-controlled proof-of-concept study in mild Alzheimer's disease
2017-004388-11Phase 2Completed
- Sponsor
- CervoMed
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Neflamapimod with Placebo (2 arms). Primary endpoint: Combined change in HVLT-R immediate and delayed recall z-scores. Started Feb 2018; status: completed.
02
Drugs
neflamapimod
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-004388-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004388-11.